Lido Advisors LLC Has $3.91 Million Stock Holdings in Kenvue Inc. $KVUE

Lido Advisors LLC lessened its stake in Kenvue Inc. (NYSE:KVUE) by 12.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 230,725 shares of the company’s stock after selling 32,145 shares during the quarter. Lido Advisors LLC’s holdings in Kenvue were worth $3,905,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in KVUE. Physician Wealth Advisors Inc. increased its stake in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares during the last quarter. Elyxium Wealth LLC acquired a new position in shares of Kenvue during the 4th quarter worth $26,000. SBI Securities Co. Ltd. increased its stake in shares of Kenvue by 82.4% during the 4th quarter. SBI Securities Co. Ltd. now owns 2,273 shares of the company’s stock worth $39,000 after purchasing an additional 1,027 shares during the last quarter. Atlantic Union Bankshares Corp increased its stake in shares of Kenvue by 184.1% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 2,619 shares of the company’s stock worth $43,000 after purchasing an additional 1,697 shares during the last quarter. Finally, Leonteq Securities AG acquired a new position in shares of Kenvue during the 4th quarter worth $45,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $17.72 on Monday. The company has a current ratio of 0.98, a quick ratio of 0.70 and a debt-to-equity ratio of 0.67. The company has a fifty day simple moving average of $17.37 and a 200 day simple moving average of $17.48. The company has a market cap of $34.01 billion, a P/E ratio of 20.84, a P/E/G ratio of 1.34 and a beta of 0.54. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 EPS. On average, sell-side analysts predict that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were issued a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is currently 97.65%.

Analyst Ratings Changes

Several research analysts have recently commented on KVUE shares. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Barclays dropped their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Argus upgraded shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Citigroup dropped their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $19.33.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.